Company news
TRON Group Inc. news in 2024
TRON Group Inc.'s news releases, calls and decks from 2024, newest first.
PRX-3140, a 5-HT4 Agonist and Sigma-1 Agonist/Antag., Modulates Glucocorticoid Insulin Suppression and Cortisol Levels
December 11, 2024
Nanopharmaceutics Announces Initiation of Clinical Study of Oral Tetrathiomolybdate Capsules in Breast Cancer Patients
October 10, 2024
Nanopharmaceutics, Inc. (TGRP) Changes Corporate Name back to TRON Group, Inc. and forms wholly-owned Nanopharmaceutics Subsidiary
June 5, 2024
Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa
May 13, 2024